ClinicalTrials.gg
CompletedNCT06436963Updated May 31, 2024

Exploring the Application of Narrative Medicine Combined With Case-Based Learning in the Standardized Training of General Practice Residents

An interventional study of narrative medicine training combined with CBL training and CBL training in Narrative Medicine and Case-based Learning, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Completed at 1 site in China. Open to participants aged 24 Years to 28 Years. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jul 2022, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
24 Years to 28 Years
Sex
All
01

Study summary

This was a prospective, longitudinal, single-center nonrandomized controlled study. A total of 36 first- and second-year general practice residents of Zhejiang University School of Medicine were voluntarily enrolled in the experimental group. The remaining 9 residents served as a control group. The experimental group received narrative medicine training combined with CBL training. The control group received normal CBL training. None of the participants had previously had any training in narrative medicine. Teaching evaluation scores were measured for all subjects at baseline and 1 year after the training.

02

Conditions studied

  • Narrative Medicine
  • Case-based Learning

Browse trials for

03

In context

Narrative Medicine

20 studies on the registry are indexed under Narrative Medicine; 8 are open to participants now.

This study's enrollment of 45 is below the median of 60 across 12 interventional studies indexed under Narrative Medicine.

Browse Narrative Medicine studies →

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years to 28 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • first- and second-year general practice residents of Zhejiang University School of Medicine

Exclusion criteria

Exclusion Criteria:

  • third-year general practice residents of Zhejiang University School of Medicine
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    narrative medicine training combined with CBL training

    The experimental group received narrative medicine training combined with CBL training

    Behavioral: narrative medicine training combined with CBL training

  • Active comparator
    CBL training

    The control group received normal CBL training

    Behavioral: CBL training

Interventions

  • Behavioralnarrative medicine training combined with CBL training

    The experimental group received narrative medicine training combined with CBL training.

  • BehavioralCBL training

    The control group received normal CBL training.

06

What researchers measure

Primary outcomes

  1. Satisfaction Survey of Residents in the Experimental Group

    The satisfaction survey was divided into five levels, ranging from "strongly agree" to "strongly disagree". The higher percent of agree means better result.

    Time frame: 12 months

  2. Comparison of the SEGUE scale scores Between the Experimental Group and the Control Group

    The SEGUE scale scores were generated by assigning a value of "1" for "yes", "0" for "no" and "0.5" for "cannot answer". High scores indicate stronger clinical communication skills.

    Time frame: 12 months

  3. Comparison of the JSE-S scale scores Between the Experimental Group and the Control Group

    The JSE-S scale scores adopts a 7-point Likert scale ranging from "strongly disagree" to "strongly agree". The higher total score indicating a greater level of empathy.

    Time frame: 12 months

  4. Comparison of the SEGUE scale in Different Grades Before and After Training in the Experimental Group

    The SEGUE scale scores were generated by assigning a value of "1" for "yes", "0" for "no" and "0.5" for "cannot answer". High scores indicate stronger clinical communication skills.

    Time frame: 12 months

  5. Comparison of the JSE-S scale in Different Grades Before and After Training in the Experimental Group

    The JSE-S scale scores adopts a 7-point Likert scale ranging from "strongly disagree" to "strongly agree". The higher total score indicating a greater level of empathy.

    Time frame: 12 months

07

Study locations

1 site
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Dec 2023, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2024
First posted
May 31, 2024
StartActual
Jul 1, 2022
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06436963
Responsible party
Sponsor
First posted
May 31, 2024
Start date
Jul 1, 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
May 31, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion